Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3846-3855

  Wong, Harvey ^a   Choo, Edna F ^a   Alicke, Bruno ^a   Ding, Xiao ^a   La, Hank ^a   McNamara, Erin ^a   Theil, Frank Peter ^a,b   Tibbitts, Jay ^a   Friedman, Lori S ^a   Hop, Cornelis E C A ^a   Gould, Stephen E ^a  

^a GENENTECH INC   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DASATINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; SUNITINIB; TRASTUZUMAB; VISMODEGIB;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG RESPONSE; FEMALE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIMULATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863904225     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0738     Document Type: Article

References (38)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5. (Pubitemid 39173511)
2. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837-44. (Pubitemid 38519762)
3. Kelland LR. "Of mice and men": values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-36. (Pubitemid 38519761)
4. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 2008;65:200-11. (Pubitemid 351174052)
5. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived- but they can be improved. Cancer Biol Ther 2003;2:S134-9.
6. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31. (Pubitemid 32522115)
7. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39. (Pubitemid 37204044)
8. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003;31:510-8. (Pubitemid 36444157)
9. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47:357-400.
10. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-17. (Pubitemid 29082094)
11. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010;70:4481-9.
12. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66: 8163-71. (Pubitemid 44299184)
13. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth-factor receptor. Oncogene 1992;7:1859-66.
14. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin Cancer Res 2011;17:4682-92.
15. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64:1094-101. (Pubitemid 38176915)
16. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software 1997. Los Angeles: Biomedical Simulations Resource.
17. Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic (PK/PD) data. In:D'Argenio DZ, editors. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Boston: Kluwer; 2004. p. 135-63.
18. Von Hoff D, Lorusso P, Rudin C, Reddy J, Yauch R, Tibes R, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
19. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Onc 2004;15: 1358-65. (Pubitemid 39295024)
20. Kalofonos HP, Nicolaides C, Samantas E, Mylonakis N, Aravantinos G, Dimopoulos MA, et al. A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Am J Clin Oncol 2002;25: 23-30. (Pubitemid 34131023)
21. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18. (Pubitemid 19245110)
22. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32. (Pubitemid 19098135)
23. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
24. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002;8:3646-57. (Pubitemid 35424754)
25. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25: 4793-9. (Pubitemid 350086483)
26. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
27. Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope 2010;120:2456-9.
28. Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8.
29. Kaye SB, Fehrenbacher L, Holloway R, Horowitz N, Karlan B, Amit A, et al. A phase 2, randomized, placebo-controlled study of hedgehog (HH) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2(nd) or 3(rd) complete remission (CR). Ann Oncol 2010;21:(Supplement 8) viii11.
30. Berlin J, Bendell J, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC). Ann Oncol 2010;21:(Supplement 8) viii10.
31. Houghton JA, Williams LG, Loftin SK, Cheshire PJ, Morton CL, Houghton PJ, et al. Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992;30:423-32.
32. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
33. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-30. (Pubitemid 46424253)
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
35. Wong SY, Reiter JF. Wounding mobilizes hair follicle stem cells to form tumors. Proc Natl Acad Sci U S A 2011;108:4093-8.
36. Scales S, de Sauvage F. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-12.
37. Yauch R, Gould S, Scales S, Tang T, Tian H, Ahn C, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455: 406-10.
38. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-40. (Pubitemid 350022448)